Learn more about the discoveries and innovations that take place at MSK every day. Search by keywords: 11 News Items found MSK Expands Collaboration with Curadev Through MSK Therapeutics Accelerator Program Friday, June 20, 2025 Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874-SI, Curadev’s first-in-class allosteric stimulator of interferon genes (STING) agonist for solid tumors. MSK iHub Challenge 2025 Cohort Now Open for Applications Wednesday, June 4, 2025 Memorial Sloan Kettering Cancer Center (MSK) is accepting applications for the 2025 Cohort of the MSK Innovation Hub (iHub) Challenge program. Digital health companies with innovations leveraging AI to address critical issues in the drug discovery process are encouraged to apply. MSK Therapeutics Accelerator Launches New Cohort Program Wednesday, April 30, 2025 Scheduled to start in Summer 2025, this cohort program will facilitate tailored mentorship with MSK faculty, while providing insight into MSK's drug development resources and a pathway for future collaboration via the Accelerator. MSK Partners with PathPresenter to Integrate New AI Module for Oncology Research Monday, April 14, 2025 Memorial Sloan Kettering Cancer Center (MSK) is partnering with PathPresenter, a leader in digital pathology workflow software, to integrate DeepLIIF, MSK’s new artificial intelligence (AI) algorithm, into PathPresenter’s image management platform for oncology research. Memorial Sloan Kettering Cancer Center and AWS to Accelerate AI-Driven Cancer Innovation Monday, March 10, 2025 Uniting MSK’s research and clinical expertise with AWS’s advanced cloud technologies is a bold step towards addressing one of the world’s most pressing health challenges. MSK’s WOUND-Q™ Questionnaire is FDA-Qualified as a Medical Device Development Tool Thursday, January 23, 2025 The U.S. Food and Drug Administration (FDA) qualified MSK’s WOUND-Q™ questionnaire as a Medical Device Development Tool (MDDT) in November 2024. MSK Presents Significant Data Study Findings to FDA Tuesday, January 14, 2025 The global clinical research community is facing a clear imperative to move beyond traditional manual data management methods in order to improve data capture, integrity, and exchange, while pursuing other related efficiencies. Arcascope Joins the MSK Innovation Hub Friday, January 3, 2025 Arcascope, a leading digital health company specializing in sleep and circadian medicine, recently became the most recent company to join the MSK Innovation Hub in October 2024. MSK Joins Global Clinical Research Innovation Task Force Tuesday, December 17, 2024 Memorial Sloan Kettering Cancer Center (MSK) is the first academic research institution worldwide to join a major global initiative focused on revolutionizing clinical trial administration. Meet MSK Evidence-Based Practice (EBP) Consulting Wednesday, November 20, 2024 An expert team within the Nursing Department at MSK has recently launched a new program called MSK Evidence-based (EBP) Consulting. Pagination Load More Book traversal links for Partnering Opportunities Previous Success Stories Next MSK Expands Collaboration with Curadev Through MSK Therapeutics Accelerator Program